Simple Summary Immune checkpoint inhibitor (ICI) therapy has recently become the
standard treatment for advanced hepatocellular carcinoma (HCC); however, clinical …

Despite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common
form of liver cancer, remains a major public health problem worldwide. The immune …

Background The high recurrence rate after liver resection emphasizes the urgent need for
neoadjuvant therapy in hepatocellular carcinoma (HCC) to enhance the overall prognosis …

Over the last several decades, a number of new treatment options for patients with
hepatocellular carcinoma (HCC) have been developed. While treatment decisions for some …

Simple Summary Hepatocellular carcinoma (HCC) is a common cause of cancer-related
deaths worldwide. During the early stages of the disease, HCC can be treated with surgery …

Objective Selecting interventions for patients with solitary hepatocellular carcinoma (HCC)
remains a challenge. Despite gross classification being proposed as a potential prognostic …

Introduction: While combination of stereotactic body radiotherapy (SBRT) and
immunotherapy are promising, their efficacy and safety have not been compared with SBRT …

Simple Summary Hepatocellular carcinoma (HCC) is one of the most prevalent and
devastating malignancies worldwide. An ongoing phase-II clinical trial assesses the efficacy …

Hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI) have dismal
prognosis and there are no standard perioperative therapies. This phase 2 trial …

Introduction: Transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor
(triple therapy) has displayed encouraging clinical outcomes for unresectable hepatocellular …